AzTrials
AzTrials

Health, SubjectiveNCT05370027

Investigation of the Effect of Unilateral Right, Unilateral Left and Bilateral Applications of Transcutaneous Auricular Vagus Nerve Stimulation on Autonomic Nervous System Activity in Healthy People

A study testing Transcutaneous Auricular Vagus Nerve Stimulation in people with Health, Subjective, run by Bahçeşehir University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The vagus nerve is one of the main components of the parasympathetic nervous system, which oversees a wide variety of important bodily functions, including mood control, immune response, digestion, and heart rate. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Health, Subjective
What is being tested?
Transcutaneous Auricular Vagus Nerve Stimulation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
No sites listed yet
Study dates
15 Jul 2022to 15 Sep 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Volunteering to participate in the study
  • Have signed the informed consent form
  • The volunteer has no disease before or during the study
  • Absence of menstrual cycle period in female volunteers
  • The subject did not drink alcohol 24 hours before the study

Who cannot join

  • Cases unwilling to continue the study.
  • Having a respiratory disease and starting to use drugs
  • Having a disease related to the cardiac system and starting to use drugs
  • The presence of any chronic disease and the use of a drug related to it

Trial locations and contacts

No sites are listed yet.

Berkay Eren E. PEHLIVANOGLU, MSc, PhD(c) contact

00905073337972 ext. Tur

fzt.berkayerenpehlivanoglu@gmail.com

About this study

The vagus nerve is one of the main components of the parasympathetic nervous system, which oversees a wide variety of important bodily functions, including mood control, immune response, digestion, and heart rate. It is the tenth cranial nerve originating from the medulla oblongata in the central nervous system and is the longest cranial nerve. It starts from the medulla and progresses to the colon. It mainly innervates the thoracic and abdominal organs. It has an obvious effect on the autonomic nervous system, especially on parasympathetic activity. When the literature is examined, it has been proven by various studies that vagus nerve stimulation has effects on the regulation of the autonomic system. Vagus nerve stimulation with different methods has been investigated over the years and the effectiveness of several different methods has been proven. There are both invasive and non-invasive (transcutaneous) techniques for vagus nerve stimulation. The first experiments were developed on invasive applications, and then non-invasive applications began to emerge.

Today, the most used devices and stimulation models were approved by the FDA in the 1990s for use in patients with drug-resistant epilepsy. In the middle of the first decade of the 2000s, the FDA approved the use of these devices for drug-resistant depression. These application methods have therapeutic effects for a wide variety of conditions, including heart failure, obesity, migraine, Alzheimer's, inflammation, chronic pain, and tinnitus. Invasive intervention is not necessary to perform this procedure. Direct stimulation of afferent nerve fibers in the ear can produce a similar effect without surgical intervention. Non-invasive vagus nerve stimulation may affect human physiology and be a simple and inexpensive alternative to invasive vagus stimulation. It has been shown on different subjects that non-invasive stimulation of the tragus in the ear increases the activation in the parasympathetic system and decreases the sympathetic activity. This indicates that tragus stimulation may be a viable treatment for some disorders in which autonomic activity is compromised.

While the general mechanism has been explained in this way, there is no definite information in the literature about which ear from the right single ear, double ear or left single ear will be applied in Transcutaneous Auricular Vagus Nerve Stimulation applications. While specifying the application techniques, an objective scientific study about whether there is a difference between Unilateral Right, Unilateral Left and Bilateral Applications or which of them gives more effective results will be a guide for further studies. The purpose of the study, planning to carry out is to seek an answer to one of the questions that come to mind for standardization. The main question we seek to answer is whether there is a difference between Unilateral Right, Unilateral Left and Bilateral Applications while specifying the application techniques, or which of them gives more effective results. This studies main goal is to set up this study in order to seek answers about which application style will produce results and to provide a guide for further studies.

Being tested
Transcutaneous Auricular Vagus Nerve Stimulation
Keywords
vagus nerve, vagus nerve stimulation, transcutaneous auricular vagus nerve stimulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcutaneous Auricular Vagus Nerve StimulationDevice

    Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.

Study groups in NCT05370027
Study groupRoleWhat they receive
1st GroupExperimentalWith the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be taken and the application will be made from the right ear. Then, the application will be performed on both ears with a 48-hour break.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation
2nd GroupExperimentalWith the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the right ear with a break for 48 hours.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation
3rd GroupExperimentalWith the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be taken and the application will be made from the left ear. Then, the application will be performed on both ears with a 48-hour break.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation
4th GroupExperimentalWith the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the left ear with a break for 48 hours.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation
5th GroupExperimentalWith the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the left ear. Then, the application will be performed on the right ear with a break for 48 hours.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation
6th GroupExperimentalWith the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the right ear. Then, the application will be performed on the left ear with a break for 48 hours.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Heart Rate

    Omron Hem 7321 E M6 device will be used to measure heart rate

    Measured: Up to 1 week

  2. Systolic and Diastolic Blood Pressure

    Omron Hem 7321 E M6 device will be used to measure Systolic and Diastolic Blood Pressure

    Measured: Up to 1 week

  3. Evaluation of Galvanic Skin Resistance

    Bogazici University GSR device will be used to measure Galvanic Skin Resistance

    Measured: Up to 1 week

  4. Heart Rate Variability

    Elite HRV device will be used to measure Heart Rate Variability

    Measured: Up to 1 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2022
  2. Study start15 Jul 2022 (estimated)
  3. Primary completion30 Aug 2022 (estimated)
  4. Study completion15 Sep 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05370027
Sponsor's protocol ID
BahcesehirU_B.Pehlivanoglu001
Status last verified
Jun 2022
First submitted
26 Apr 2022
Last updated
15 Jun 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Transcutaneous Auricular Vagus Nerve Stimulation in people with Health, Subjective, run by Bahçeşehir University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Berkay Eren E. PEHLIVANOGLU, MSc, PhD(c) (00905073337972 ext. Tur, fzt.berkayerenpehlivanoglu@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Heart Rate (time frame: Up to 1 week). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in